2. Search Result
Search Result
Results for "

Smac

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

3

Peptides

2

Natural
Products

1

Recombinant Proteins

2

Antibodies

1

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16591
    Birinapant
    40+ Cited Publications

    TL32711

    		 IAP Apoptosis HIV Cancer
    Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.
    Birinapant
  • HY-15454
    Xevinapant
    10+ Cited Publications

    AT-406; Debio 1143; SM-406

    		 IAP Apoptosis Cancer
    Xevinapant (AT-406) is a potent and orally bioavailable Smac mimetic and an antagonist of IAPs, and it binds to XIAP, cIAP1, and cIAP2 proteins with Ki of 66.4, 1.9, and 5.1 nM, respectively.
    Xevinapant
  • HY-15989
    SM-164
    Maximum Cited Publications
    54 Publications Verification

    		 IAP Apoptosis Cancer
    SM-164 is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.
    SM-164
  • HY-N0732
    Jolkinolide B
    1 Publications Verification

    		 IAP Akt Caspase NF-κB TGF-beta/Smad JAK Bacterial Apoptosis Infection Metabolic Disease Inflammation/Immunology Cancer
    Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .
    Jolkinolide B
  • HY-13208
    Xevinapant hydrochloride
    10+ Cited Publications

    AT-406 hydrochloride; Debio 1143 hydrochloride; SM-406 hydrochloride

    		 IAP Apoptosis Cancer
    Xevinapant (AT-406) hydrochloride is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). Xevinapant hydrochloride binds to XIAP, cIAP1, and cIAP2 proteins with Kis of 66.4, 1.9, and 5.1 nM, respectively. Xevinapant hydrochloride effectively antagonizes XIAP BIR3 protein in a cell-free functional assay, induces rapid degradation of cellular cIAP1 protein, and inhibits cancer cell growth in various human cancer cell lines. Xevinapant hydrochloride is highly effective in induction of apoptosis in xenograft tumors .
    Xevinapant hydrochloride
  • HY-125593
    Dasminapant

    APG-1387

    		 IAP Apoptosis Cancer
    Dasminapant (APG-1387), a bivalent SMAC mimetic and an IAP antagonist, blocks the activity of IAPs family proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). Dasminapant induces degradation of cIAP-1 and XIAP proteins, as well as caspase-3 activation and PARP cleavage, which leads to apoptosis. Dasminapant can be used for the research of hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma .
    Dasminapant
  • HY-138832
    BM-1244

    APG-1252-M1

    		 Bcl-2 Family Apoptosis Caspase PARP Cancer
    BM-1244 (APG-1252-M1) is a Bcl-xL/Bcl-2 inhibitor with Kis of 134 nM and 450 nM. BM-1244 has anti-tumor effects by inducing apoptosis and suppressing tumor growth. BM-1244 can induce cytochrome C and Smac release from mitochondria with caspase-3 and PARP cleavage. BM-1244 exhibits synergy with chemotherapy in vivo. BM-1244 can be studied in research for colorectal cancer, acute myeloid leukemia and gastric cancer .
    BM-1244
  • HY-W008235
    Fmoc-N-Me-Ala-OH

    		Amino Acid Derivatives Drug Intermediate Cancer
    Fmoc-N-Me-Ala-OH is an Fmoc-protected N-methyl-L-alanine and also a building block for solid-phase peptide synthesis. As a building block, Fmoc-N-Me-Ala-OH is used to synthesize peptidomimetic antagonists of XIAP BIR3 derived from Smac/DIABLO .
    Fmoc-N-Me-Ala-OH
  • HY-15989A
    SM-164 hydrochloride
    Maximum Cited Publications
    54 Publications Verification

    		 IAP Apoptosis Cancer
    SM-164 hydrochloride is a cell-permeable Smac mimetic compound. SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains with an IC50 value of 1.39 nM and functions as an extremely potent antagonist of XIAP.
    SM-164 hydrochloride
  • HY-P10103
    Smac-N7 peptide

    		Caspase Cancer
    Smac-N7 peptide, the seven N-terminal amino acid of the mitochondrial protein Smac (second mitochondria-derived activator of caspase), cannot pass through the cell membrane .
    Smac-N7 peptide
  • HY-125378
    SBP-0636457

    SBI-0636457; SB1-0636457

    		 IAP Cancer
    SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers .
    SBP-0636457
  • HY-15519
    LBW242

    		IAP FLT3 Cancer
    LBW242, a 3-mer and Smac mimetic, is a potent and orally active proapoptotic IAP inhibitor. LBW242 shows effects on mutant FLT3-expressing cells. LBW242 has activity against multiple myeloma, and potentiates TRAIL- and anticancer agent-mediated cell death of ovarian cancer cells .
    LBW242
  • HY-125378A
    (7R)-SBP-0636457

    (7R)-SBI-0636457; (7R)-SB1-0636457

    		 IAP Cancer
    (7R)-SBP-0636457 is the isomer of SBP-0636457 (HY-125378), and can be used as an experimental control. SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an IAP antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a Ki of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers .
    (7R)-SBP-0636457
  • HY-120434
    AEG40826

    HGS1029

    		 IAP Cancer
    AEG40826 (HGS1029), a second mitochondria-derived activator of caspases (SMAC) mimetic, is an inhibitor of apoptosis (IAP) inhibitor. AEG40826 degrades cellular IAP1 (cIAP1) and blocks TNF-α pro-survival signaling. AEG40826 can be used for cancer research .
    AEG40826
  • HY-P10104
    Smac-N7, Penetratin conjugated

    		Caspase Cancer
    Smac-N7, Penetratin conjugated is a caspase activator derived from the second mitochondria-derived activator of caspases (SMAC) .
    Smac-N7, Penetratin conjugated
  • HY-138059
    SM-433

    		IAP Apoptosis Cancer
    SM-433, a Smac mimetic, function as inhibitor of inhibitor of apoptosis proteins (IAPs). SM-433 exhibits strong binding affinity XIAP BIR3 protein with an IC50<1 μM (patent WO2008128171A2) .
    SM-433
  • HY-155294
    SM-122

    		IAP Apoptosis Cancer
    SM-122 is a monovalent Smac mimetic targeting cellular inhibitor of apoptosis protein (cIAP)-1/2. SM-122 can induce cIAP-1/2 degradation and weakly induce apoptosis in tumor cells. SM-122 can be used for the research of cancer, such as breast cancer .
    SM-122
  • HY-138059A
    SM-433 hydrochloride

    		IAP Apoptosis Cancer
    SM-433 hydrochlorid, a Smac mimetic, function as inhibitor of inhibitor of apoptosis proteins (IAPs). SM-433 hydrochlorid exhibits strong binding affinity XIAP BIR3 protein with an IC50<1 μM (patent WO2008128171A2) .
    SM-433 hydrochloride
  • HY-RS25999
    Diablo Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Diablo Rat Pre-designed siRNA Set A contains three designed siRNAs for Diablo gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Diablo Rat Pre-designed siRNA Set A
    Diablo Rat Pre-designed siRNA Set A
  • HY-RS03762
    DIABLO Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DIABLO Human Pre-designed siRNA Set A contains three designed siRNAs for DIABLO gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DIABLO Human Pre-designed siRNA Set A
    DIABLO Human Pre-designed siRNA Set A
  • HY-RS19505
    Diablo Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Diablo Mouse Pre-designed siRNA Set A contains three designed siRNAs for Diablo gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Diablo Mouse Pre-designed siRNA Set A
    Diablo Mouse Pre-designed siRNA Set A
  • HY-161473
    Apoptosis inducer 16

    		Apoptosis Cancer
    Apoptosis inducer 16 (Compound 3) is a bivalent Smac mimic that can effectively bind to BIR2 and BIR3, and exhibits cancer cell (apoptosis) inducing activity .
    Apoptosis inducer 16
  • HY-N0732R
    Jolkinolide B (Standard)

    		Reference Standards IAP Akt Caspase NF-κB TGF-beta/Smad JAK Bacterial Apoptosis Infection Inflammation/Immunology Cancer
    Jolkinolide B (Standard) is the analytical standard of Jolkinolide B (HY-N0732). This product is intended for research and analytical applications. Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis .
    Jolkinolide B (Standard)
  • HY-181532
    IAP ligand 8

    		Ligands for E3 Ligase IAP Cancer
    IAP ligand 8 is an ASX-series, non-peptidic SMAC mimetic and IAP binder with high cell permeability. IAP ligand 8 selectively targets cIAP1-BIR3, XIAP-BIR2 (with a KD of 15.8 nM for both). IAP ligand 8 serves as an IAP ligand moiety to synthesize IAP-recruiting protein degrader (IPD) (HY-181590). This IPD simultaneously forms two ternary complexes, cIAP1-A538-TEAD1 and XIAP-A538-TEAD1, and efficiently degrades TEAD1 via a dual E3 recruitment mechanism, while inducing the autodegradation of cIAP1. IAP ligand 8 and its series of degraders are applicable to targeted research on Hippo pathway-dysregulated cancers such as NF2-mutant mesothelioma .
    IAP ligand 8
  • HY-181533
    IAP ligand 9

    		Ligands for E3 Ligase IAP Cancer
    IAP ligand 9 is an ASX-series, non-peptidic SMAC mimetic and IAP binder with high cell permeability. IAP ligand 9 selectively targets cIAP1-BIR3, XIAP-BIR3, exhibits extremely weak binding affinity for XIAP-BIR2, with a KD of 100 nM for cIAP1-BIR3 and 10 nM for XIAP-BIR2. IAP ligand 9 can be used to synthesize IAP-recruiting protein degraders (IPD), and can calibrate the cell permeability and cellular-level target binding assays of the IPD molecule SNIPER (TEAD)-1 (HY-181607). IAP ligand 9 and its series of degraders can be used in the research of solid tumors such as malignant pleural mesothelioma associated with abnormal activation of the Hippo pathway .
    IAP ligand 9
  • HY-181530
    IAP ligand 6

    		IAP Cancer
    IAP ligand 6 (A250) is an IAP ligand with a Ka value of 0.1 μM for the human XIAP BIR3 domain. IAP ligand 6 binds to the XIAP BIR3 domain and serves as an alkynylpyridine scaffold for the preparation of TEAD degraders that recruit IAP. IAP ligand 6 is applicable to research related to mesothelioma .
    IAP ligand 6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: